Overview

Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Sanofi-Synthelabo
Treatments:
Docetaxel
Oxaliplatin